Literature DB >> 25900365

Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes.

Franziska Wilhelm1, Franziska Kässner2, Gordian Schmid2, Jürgen Kratzsch3, Andreas Laner4, Martin Wabitsch5, Antje Körner1, Wieland Kiess2, Antje Garten6.   

Abstract

OBJECTIVE: Insulin-like-growth factor binding protein 2 (IGFBP-2) is thought to be a marker for the phosphatase and tensin homolog (PTEN) status and activity of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. We aimed to evaluate whether or not lipoma cells of a patient with a heterozygous deletion in the PTEN gene would produce more IGFBP-2 than PTEN non deficient control cells. Moreover, we analysed the influence of pharmacological inhibitors of the PI3K/AKT/mTOR pathway on IGFBP-2 production.
DESIGN: PTEN deficient preadipocytes and control PTEN non deficient preadipocytes were differentiated in vitro and treated with the respective inhibitors. PTEN was transiently down regulated by siRNA in human preadipocytes. IGFBP-2 mRNA and protein expression and IGFBP-2 in culture supernatant were measured.
RESULTS: PTEN deficient lipoma cells were found to produce IGFBP-2 during in vitro differentiation in comparable amounts to PTEN non deficient cells. In contrast, acute down regulation of PTEN in preadipocytes resulted in enhanced production of IGFBP-2. Incubation with the PI3K inhibitors LY294002 and wortmannin decreased IGFBP-2 mRNA and protein. Neither the mTOR complex 1 inhibitor rapamycin nor PD98059, an inhibitor of MEK (mitogen-activated protein kinase kinase), showed a significant effect on IGFBP-2 production.
CONCLUSION: IGFBP-2 production in PTEN deficient preadipocytes was not influenced by PTEN deficiency or by inhibition of mTORC1 and MAPK. In contrast, inhibition of PI3K decreased IGFBP-2 expression and secretion.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Human adipocytes; IGFBP-2; PHTS; PI3K; PTEN; Rapamycin

Mesh:

Substances:

Year:  2015        PMID: 25900365     DOI: 10.1016/j.ghir.2015.03.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  3 in total

1.  Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.

Authors:  Carmela De Marco; Carmelo Laudanna; Nicola Rinaldo; Duarte Mendes Oliveira; Maria Ravo; Alessandro Weisz; Michele Ceccarelli; Elvira Caira; Antonia Rizzuto; Pietro Zoppoli; Donatella Malanga; Giuseppe Viglietto
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 2.  Potential Role of Insulin Growth-Factor-Binding Protein 2 as Therapeutic Target for Obesity-Related Insulin Resistance.

Authors:  Hatim Boughanem; Elena M Yubero-Serrano; José López-Miranda; Francisco J Tinahones; Manuel Macias-Gonzalez
Journal:  Int J Mol Sci       Date:  2021-01-24       Impact factor: 5.923

3.  Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk.

Authors:  Flavien Berthou; Cyril Sobolewski; Daniel Abegg; Margot Fournier; Christine Maeder; Dobrochna Dolicka; Marta Correia de Sousa; Alexander Adibekian; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.